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Caenorhabditis elegans is a useful model for
anthelmintic discovery
Andrew R. Burns1,*, Genna M. Luciani1,2,*, Gabriel Musso3,4, Rachel Bagg1, May Yeo1, Yuqian Zhang1,
Luckshika Rajendran1, John Glavin1, Robert Hunter1, Elizabeth Redman5, Susan Stasiuk5, Michael Schertzberg1,
G. Angus McQuibban6, Conor R. Caffrey7, Sean R. Cutler8, Mike Tyers9, Guri Giaever10, Corey Nislow10,
Andy G. Fraser1,2, Calum A. MacRae3,4, John Gilleard5 & Peter J. Roy1,2,11
Parasitic nematodes infect one quarter of the world’s population and impact all humans
through widespread infection of crops and livestock. Resistance to current anthelmintics has
prompted the search for new drugs. Traditional screens that rely on parasitic worms are costly
and labour intensive and target-based approaches have failed to yield novel anthelmintics.
Here, we present our screen of 67,012 compounds to identify those that kill the non-parasitic
nematode Caenorhabditis elegans. We then rescreen our hits in two parasitic nematode
species and two vertebrate models (HEK293 cells and zebraﬁsh), and identify 30 structurally
distinct anthelmintic lead molecules. Genetic screens of 19 million C. elegans mutants reveal
those nematicides for which the generation of resistance is and is not likely. We identify the
target of one lead with nematode speciﬁcity and nanomolar potency as complex II of the
electron transport chain. This work establishes C. elegans as an effective and cost-efﬁcient
model system for anthelmintic discovery.
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P
arasitic nematodes are estimated to infect about one quarter
of all humans and have a dramatic negative impact on
human health and productivity in developing nations1,2.
Nematode infections of agriculturally important plants and
animals also result in huge economic losses worldwide3,4.
Despite this, only a handful of anthelmintic families are
currently available. These include the benzimidazoles,
macrocyclic lactones (for example, ivermectin), imidazothiazoles
(for example, levamisole) and cyclic octadepsipeptides (for
example, emodepside), most of which were introduced decades
ago. Nematode resistance has been reported for each class of
compound, with some natural isolates showing multidrug
resistance3,5. Anthelmintic resistance is a global issue; although
some regions, such as New Zealand, have a particularly high
prevalence of resistant parasites5. Amino-acetonitrile derivatives
(AADs) such as monepantel have recently been introduced to the
market; however, resistance to this class of compounds has
already been reported6–8. While combinatorial strategies may
prolong an anthelmitic’s utility, growing resistance poses
signiﬁcant challenges for the management of parasitic infections.
One reason for the limited number of available anthelmintics
may be related to the difﬁculty in identifying lead compounds at
high throughput. The complex life cycle of parasitic nematodes,
which rely on a host for propagation, make it challenging to
examine a small molecule’s impact on these animals with the
throughput required to identify large numbers of candidate
molecules for further development. The free-living nematode
Caenorhabditis elegans may offer a convenient alternative model
system to search for new compounds that speciﬁcally kill
nematodes. C. elegans, which is B1mm in length as an adult,
can be cultured in high-throughput format for multiple
generations, allowing the identiﬁcation of molecules that perturb
the worm at any point during its life cycle9–12.
The majority of marketed anthelmintics are active against
C. elegans6,13, and the use of this model system has been
instrumental in improving the understanding of the
mechanism of action of several anthelmintic compounds,
including levamisole, benzimidazole and the amino-acetonitrile
derivatives6,13,14. Notably, the targets of each of these compounds
have been elucidated through forward genetic screens for
C. elegans mutants that resist their effects. In these screens,
C. elegans parents are randomly mutagenized and their progeny
are subsequently screened for individuals that can resist the
effects of a given bioactive molecule. ‘Drug’-resistant strains are
analysed genetically to identify the resistance-conferring mutant
gene. The most frequent resistance-conferring mutant gene
within the collection of resistant strains has been shown to
encode either the target or the targeted pathway/complex of these
bioactive molecules6,9,14.
Clearly, C. elegans is a useful model system to study anthelmintics
and offers throughput that is not possible with parasitic species. It
therefore follows that it might also be a powerful system with which
to screen for anthelmintic lead compounds, as has been suggested
over 30 years ago15. However, there have only been anecdotal
references to the use of C. elegans in the anthelmintic screening
programs of the pharmaceutical industry16–20, the details of which
have not been publically described. Thus, whether bioactivity in
C. elegans is generally predictive of bioactivity in parasitic nematode
species remains unknown.
Here, we describe our screen for anthelmintic lead compounds
using whole C. elegans nematodes as the primary model system.
We screened 67,012 distinct small molecules for their ability to
kill C. elegans and re-screened our hits in two widely studied
parasitic nematode models: Cooperia onchophora, a parasite of
cattle, and Haemonchus contortus, a parasite of sheep5,21. We
counter-screened the nematicidal molecules in two vertebrate
models of development (HEK293 cells and zebraﬁsh) and
identiﬁed a set of molecules that kills nematodes but may be
inactive in vertebrates. In an effort to identify the protein targets
for 39 nematicides, we screened more than 19 million mutant
C. elegans for resistance. We identiﬁed the target of one family of
these lethal molecules that is closely related to nematicides that
have recently been introduced to the market22,23, demonstrating
the value of C. elegans as a model system for the discovery of
useful nematicidal molecules.
Results
Molecules that kill C. elegans are likely to kill parasites. To
identify nematicidal compounds, we screened 67,012
commercially available small drug-like molecules for those that
induce obvious phenotypes in C. elegans at a concentration of
60 mM or less (see Fig. 1a and Supplementary Data 1). From our
preliminary screens, we identiﬁed 627 bioactive molecules that
we call ‘worm actives’ or ‘wactives’. Rescreening revealed 275
wactives that kill C. elegans at a concentration of 60mM or less
(see Supplementary Data 1). By contrast, none of the 182
molecules chosen at random from the set of 67,012 compounds
killed C. elegans (see Supplementary Data 1).
We next screened the wactive library against the nematode
parasites C. onchophora and H. contortus (Fig. 1a). We chose
these two species, both of which are from the same phylogenetic
clade as C. elegans (clade V), because we could screen them using
similar methods that we used to screen C. elegans and because
many important parasites of humans and domestic livestock are
from clade V. We collected nematode eggs from infected animals
and tested whether the wactives could kill the eggs or hatched
animals (see Methods). Of the 275 wactives that killed C. elegans,
129 and 116 killed at least 90% of the C. onchophora and
H. contortus animals, respectively, and 103 killed all three
nematode species (Fig. 1b). Of the 182 randomly chosen
molecules, none killed C. onchophora and ﬁve killed H. contortus.
Hence, molecules that kill C. elegans are more than 15 times more
likely to kill these parasitic nematodes compared with randomly
chosen molecules (Fig. 1c).
We counter-screened the wactive and random control libraries
for activity against two vertebrate models: Danio rerio (zebraﬁsh)
and HEK293 cells (Fig. 1a). Fifty-nine of the 275 wactives that kill
C. elegans and 28 of the random molecules either kill or cause
substantial morbidity in zebraﬁsh (see Methods), representing an
enrichment of o1.4-fold (Fig. 1c). Similarly, 76 of the 275
wactives that kill C. elegans and 40 of the random molecules
caused substantial growth defects in HEK293 cells (see Methods),
representing an enrichment of o1.3-fold (Fig. 1c). These results
suggest that C. elegans is a useful model system with which to
identify molecules that are lethal in parasitic nematodes, without
generally being cytotoxic in vertebrates.
On analysis of chemical properties, we found that nematicidal
compounds had a higher average computed octanol/water
partition coefﬁcient (logP; 3.9 versus 3.2, Po10 13; Student’s
t-test) and lower average molecular weight (273 versus 328,
Po10 20; Student’s t-test) when compared against the complete
set of 67,012 compounds (Supplementary Fig. 1). This suggests
that molecules that are smaller and with greater lipid-solubility
might be more effective nematicides.
Structure analyses reveal 30 classes of anthelmintic leads. To
further characterize our 275 C. elegans-lethal molecules, we
organized them into three separate groups based on their
phylogenetic bioactivity proﬁles (Fig. 2a). Group 1 contains 102
molecules that are lethal to only one or two of the three nematode
species tested, but are non-lethal to zebraﬁsh and HEK cells.
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Group 2 contains 67 compounds that are lethal to all three
nematode species, but are non-lethal to zebraﬁsh and human
cells. Group 3 contains the remaining 106 compounds that are
lethal to ﬁsh or HEK cells, and have varied bioactivity in different
nematode species. In particular, the 67 molecules in group 2
represent potentially ideal anthelmintic leads; they have activity
across multiple nematode species, and appear not to affect
vertebrates.
To better understand the structural relationships that exist
among our C. elegans-lethal compounds, we constructed a
structure similarity network that connects molecules if they have
a pairwise Tanimoto/FP2 similarity40.55 (Fig. 2b; see Methods).
This network contains 19 isolated clusters composed of three
molecules or more, leaving 72 unconnected singletons or pairs.
Each cluster represents a unique structural family that could, in
principle, target a single protein, although the larger C1 and C2
clusters may contain multiple subfamilies of structures. The 67
group 2 molecules are distributed across 12 clusters, two pairs
and 16 singletons, representing 30 structurally unique classes of
anthelmintic leads that may target 30 or more distinct protein
targets.
To estimate our ability to improve upon the biological activity
of the 67 group 2 molecules through medicinal chemistry, we
compared the structural similarity of each of these wactives with
the 67,012 molecules that we screened (see Methods;
Supplementary Data 1). We reasoned that the fraction of
molecules within a family of structural analogues that are
bioactive may be predictive of the ability to create novel
analogues that are bioactive, some of which may have improved
bioactivity. We found that 38 (57%) of the 67 wactives are
members of a structural analogue family (based on a pairwise
Tanimoto/FP2 similarity score of 0.55 or greater) for which more
than 10% are lethal to C. elegans (Supplementary Fig. 3).
Considering only the 18 group 2 wactives that are excluded from
the 19 structural clusters in Fig. 2b, we found that 10 (56%) are
members of a structural analogue family for which more than
10% are lethal to C. elegans. These results suggest that many of
the group 2 wactives have the potential for improvement through
medicinal chemistry efforts.
Modest structural changes impact phylogenetic speciﬁcity. The
C3, C13 and C14 clusters in Fig. 2b are composed exclusively of
molecules that selectively kill nematodes, suggesting that these
families may be targeting nematode-speciﬁc proteins. The
remaining 16 structural families contain at least one molecule that
is lethal to either ﬁsh or human cells, suggesting that if the
compounds in a cluster target a single protein, the target might be
conserved in vertebrates. At the very least, these 16 clusters
suggest that relatively modest structural changes can alter the
species selectivity of the molecules in a family. To further explore
the divergence of species selectivity within these 16 structural
families, we focused on pairs of molecules that have a Tanimoto/
FP2 pairwise similarity score of 80% or more, and for which one
molecule in the pair speciﬁcally kills nematodes (group 2 mole-
cules) and the other kills both nematodes and a vertebrate model
(group 3 molecules). Seventeen pairs of molecules satisfy these
criteria (Supplementary Fig. 2). Inspection of the structural dif-
ferences of the individual molecules within each pair reveals that
very small structural changes can restrict a molecule’s bioactivity
to nematodes. For example, wact-1, wact-433 and wact-434 in
cluster 18 are identical except that an ethyl group in wact-434
replaces the halogen of wact-1 and wact-433. The halogen sub-
stitution destroys the core molecule’s bioactivity in ﬁsh and
restricts its activity to nematodes. Medicinal chemistry often
yields structural analogues that have reduced or abolished
bioactivity. However, our structure–activity analysis has revealed
analogues that have not lost bioactivity but have instead become
phylogenetically restricted.
Genetic resistance to most nematicides is not easily induced.
Forward genetic screens with C. elegans have been previously
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Figure 1 | Molecules that kill C. elegans are enriched for those that are lethal to parasitic nematodes. (a) Flow chart outlining the multi-organism
small-molecule screening pipeline. (b) Venn diagram showing the overlap of wactive library molecules that kill C. elegans, Cooperia oncophora and
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used to identify the targets of bioactive compounds6,9,14. Here, we
chose 39 compounds from the set of 275 C. elegans-lethal
wactives to pursue their target genetically (see Methods;
Supplementary Data 1; Fig. 2). These 39 molecules span 19
distinct structural classes (Fig. 2b), and the majority of these
compounds are found in group 2, which are lethal to all three
nematodes tested and non-lethal to zebraﬁsh and HEK293 cells
(Fig. 2a).
To identify mutants that are resistant to speciﬁc compounds,
we randomly mutagenized wild-type C. elegans parental (P0)
worms using chemical mutagens (see Methods) and screened for
animals that resist lethality in either the ﬁrst (F1) or second (F2)
generation. Resistant mutants that arise in F1 screens are
dominant and typically encode missense mutations that confer
resistance against antagonists, while resistance-conferring muta-
tions in F2 animals are typically recessive reduction-of-function
mutations that confer resistance to agonists24. Molecules against
which F1 screens did not yield resistant mutants were screened
again for F2-resistant mutants. We performed F1 screens for all
39 lethal molecules, and F2 screens for 29 of the 39 compounds
(Supplementary Table 1). In total, we screened over 19 million
mutant genomes and we were able to isolate resistant mutants
against only six of the 39 molecules (Supplementary Table 1).
Wact-11-resistant mutants show intra-family cross-resistance.
Wact-11, wact-12 and wact-127 are three of the molecules against
which we could generate resistant mutants (Supplementary
Table 1). These three molecules are part of the C10 cluster
(Fig. 2b), which we refer to as the ‘wact-11 family’, and share an
ethyl benzamide moiety (Fig. 3). In total, we isolated 37 mutants
that resist the wact-11 family members at a rate of one mutant per
100,000 genomes screened (Supplementary Table 1). Using a
representative set of 21 mutants, we performed a detailed dose-
response analysis of each mutant against wact-11 and the struc-
turally unrelated nematicide wact-2 in liquid media
(Supplementary Fig. 4). All of the tested mutants show at least
some resistance to wact-11, but not to wact-2, indicating that they
are speciﬁcally resistant to wact-11.
Given their structural similarity, we hypothesized that each
compound within the wact-11 family may share the same
mechanism of action. If true, then mutants that were isolated
based on their resistance to one wact-11 family member will resist
the lethality that is induced by other family members. To test this,
we performed a dose-response analyses of two wact-11-family
resistant mutants (isolated based on their respective resistance to
wact-11 and wact-12) against all nine wact-11-family members.
Both mutants were resistant to all nine wact-11-family members
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Figure 2 | Nematode selectivity and structural proﬁling of the 275 C. elegans-lethal molecules. (a) Heat map indicating the lethality (or lack thereof)
induced by each of the 275 C. elegans-lethals in two species of parasitic nematode, as well as zebraﬁsh embryos and human embryonic kidney (HEK) cells.
For each species, the number of molecules that induce lethality is indicated to the right of the heat map. The molecules segregate into three groups based
on their nematode selectivity and cross-species lethality. If a genetic screen for resistant mutants was performed for a given molecule, this is indicated, as
well as the outcome of the screen. (b) Network based on the structural similarity of the 275 C. elegans-lethal molecules. Nodes represent molecules, and
edges connect molecules with a pairwise Tanimoto/FP2 score40.55 (see Methods). The group to which each molecule belongs is indicated by the node
ﬁll colour, whereas the genetic screen information is indicated by the node border colour. In the legend, the number of molecules is indicated in
parentheses. The 19 clusters containing three or more molecules are named C1 to C19. The wact-11 structural family (cluster C10) is magniﬁed, and the
names of each molecule in the family are indicated.
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(Fig. 3), supporting the idea that all nine members of the wact-11
family act by the same mechanism.
The wact-11 family inhibits worm mitochondrial complex II.
To identify candidate targets of the wact-11-family, we sequenced
the genomes of 33 resistant mutants to identify mutated genes
common to multiple strains (Supplementary Data 2 and 3). Ten
strains had missense mutations in sdhb-1, a different set of 16
strains had a missense mutation in sdhc-1 (otherwise known as
mev-1), six other strains had missense mutations in sdhd-1 and
one remaining strain had no commonly mutated gene (Table 1).
By contrast, no other gene is represented by distinct mutant
alleles in more than four of the 33 strains, and none of the sdh
genes are mutated in 36 strains that resist the effects of two other
unrelated molecules (A.R.B., Houtan Moshiri and P.J.R., unpub-
lished results). Consistent with the isolation of the majority of
these mutants in F1 screens, none of the sdh mutations are
nonsense, frame-shifts or deletions that would be indicative of
loss-of-function. Instead, the missense mutations change four
unique residues in SDHB-1, seven unique residues in SDHC-1
and three unique residues in SDHD-1 (Table 1).
SDHB-1, SDHC-1 and SDHD-1, along with SDHA-1, are the
four protein subunits of C. elegans mitochondrial complex II25
(otherwise known as succinate dehydrogenase or sdh), which
couples the citric acid cycle to the electron transport chain and is
highly conserved among eukaryotes26. Complex II couples the
oxidation of succinate to fumarate, with the reduction of
ubiquinone to ubiquinol26. Eukaryotic complex II has at least
one ubiquinone-binding site, referred to as the Qp site or Q-site,
that exists at the intersection of the SDHB, SDHC and SDHD
subunits. In contrast, the succinate-binding site is found
exclusively in the SDHA subunit.
A number of Q-site inhibitors are used as fungicides and
interest in their use against nematodes is growing27–29. For
example, ﬂutolanil has been shown to inhibit complex II from the
parasitic nematode Ascaris suum in vitro, and a co-crystal
structure of ﬂutolanil with this complex has been solved30,31. We
rendered an image of this crystal structure and highlighted the
corresponding 14 orthologous residues that are mutated in the
wact-11-resistant C. elegans mutants (Fig. 4a). Despite residing in
three distinct proteins, all the 14 residues cluster around the
Q-site where ﬂutolanil is bound. Furthermore, of the 12 residues
that are within 4 angstroms of ﬂutolanil’s central mass, four are
mutated in our wact-11-family resistant mutants (Fig. 4b).
Finally, the most frequently mutated residue in our screen is in
SDHC-1’s R74, which corresponds to Ascaris’ R89 of SDHC
that likely makes electrostatic contacts with the benzene ring
of ﬂutolanil’s 2-triﬂuoromethyl-benzamide group30,31. Like
ﬂutolanil, wact-11 also has a 2-triﬂuoromethyl-benzamide
group, and all wact-11 family members have the benzamide
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Figure 3 | Wact-11 and wact-12 resistant mutants are cross-resistant to all nine wact-11-family members. (a) The wact-11-family core structure and the
structure of an unrelated molecule, wact-2, which was used as a negative control throughout this work. (b) Heat maps of the wact-11-family dose-response
experiments with wild-type worms (N2 strain), as well as two mutant strains, RP2674 and RP2698, isolated as being resistant to wact-12 and wact-11,
respectively. The dose-response experiments were carried out using a 96-well plate liquid-based assay (see Methods). White indicates that there were
more than 50 worms in three out of four replicate wells. Pink indicates that there were between 12 and 50 worms in three out of four replicate wells. Red
indicates that there were between 0 and 11 worms in three out of four replicate wells. In the case of ties, the higher number prevailed (for example, at a
given concentration, if two wells had 55 worms, and the other two wells had 20 worms, the chemical would be scored as having more than 50 worms). The
R1 and R2 groups are indicated for each wact-11-family member. Wact-2 is used here as a negative control.
Table 1 | Complex II residue changes for the wact-11-family-
resistant strains.
Number
of
strains
C. elegans
mutated
gene
C. elegans
residue
change
Ascaris suum
orthologous
residue
Human
orthologous
residue
1 sdhb-1 P145L P127 P131
2 sdhb-1 H146Y H128 H132
6 sdhb-1 P211L P193 P207
1 sdhb-1 I260N I242 I246
3 sdhc-1 T66I T81 P64
1 sdhc-1 G71E G86 I69
8 sdhc-1 R74K R89 R72
1 sdhc-1 G77D G92 G75
1 sdhc-1 C78Y C93 I76
1 sdhc-1 G133E G148 G131
1 sdhc-1 F136S F151 H134
1 sdhd-1 H84Q H95 H98
4 sdhd-1 D95N D106 D109
1 sdhd-1 A97T G108 V111
1 ?
33 total
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moiety. Taken together, our observations suggest that the wact-
11-family kills nematodes by binding the Q-site of complex II,
and consequently disrupts the interaction of ubiquinone with the
complex. Furthermore, the viability of the resistant mutants
suggests that the missense mutations alter the Q-site in a way that
preserves its function.
We directly tested whether wact-11 and wact-12 can inhibit the
enzymatic activity of wild-type C. elegans complex II in vitro
(see Methods). We found that both molecules could inhibit
complex II activity with IC50s of 7.4 nM and 5.7 nM, respectively
(Table 2, Supplementary Fig. 5). We also tested whether these
molecules could inhibit complex II from two independently isolated
wact-11-resistant mutants that each harbour the SDHC-1(R74K)
missense mutation. We found that complex II from these mutants
is insensitive to the molecules up to the highest concentration tested
(10mM; Table 2). As a control, we tested whether wild-type and
mutant complex II activity could be inhibited by malonate, which
inhibits SDHA-1’s succinate-binding activity. We found that
malonate inhibits the wild-type complex II to a similar extent as
the mutant enzymes (Table 2, Supplementary Fig. 5). These results
provide evidence that: (i) mutations in complex II confer resistance
to the wact-11-family and (ii) wact-11-family members kill worms
by speciﬁcally inhibiting complex II at the Q-site.
A SAR analysis reveals potent wact-11 analogues. We per-
formed a focused structure–activity relationship (SAR) analysis
with 16 purchasable analogues of the wact-11 family to better
understand the structural elements that impact its bioactivity. We
ﬁrst tested the ability of the analogues to inhibit complex II
activity in vitro. In general, the presence of an electron-with-
drawing group at the 2’ position of the benzamide benzene ring
favours complex II inhibition because the absence of such a group
decreases the inhibition by at least 86-fold relative to wact-11 (see
wact-11b and wact-11k in Table 2). This observation is consistent
with the proposed binding mechanism of ﬂutolanil (see above).
The position of the triﬂuoromethyl group is also important
because relocating it to the 4’ position (see wact-11 g in Table 2)
decreases complex II inhibition by at least 1,300-fold. The R2
phenyl ring of wact-11 promotes complex II inhibition because
removing it (see wact-11i) decreases inhibition 44-fold. Finally,
having chloride groups attached to the R2 phenyl ring promotes
complex II inhibition. For example, the two most potent analo-
gues, wact-11 f and wact-11m, have IC50 values of 1 nM, which is
over 7-fold lower than that of wact-11, and both of these com-
pounds have electron-withdrawing groups at the 20 position of
their benzamide benzene rings, as well as chloride groups at the 20
and 40 positions of their R2 phenyl rings.
We next tested the in vivo potency of the analogues, and found a
positive correlation between the in vitro IC50 and the in vivo LD100
(dose lethal to 100% of animals tested) values (Table 2; Pearson’s
correlation coefﬁcient¼ 0.85), further strengthening the argument
that complex II is the in vivo target of the wact-11-family. The
difference between the in vitro and in vivo potencies reported in
Table 2 is likely due to the resistance of intact C. elegans worms to
the accumulation of exogenous small molecules32. Notably, the two
most potent analogues, wact-11 f and wact-11m, have LD100 values
in C. elegans of 0.469mM (Table 2). Thus, our SAR analysis
revealed nematicides with submicromolar potency.
Few known complex II inhibitors kill C. elegans. In addition to
ﬂutolanil, we found other commercial complex II Q-site inhibi-
tors that have structural similarity to the wact-11-family
(Supplementary Fig. 6). In particular, ﬂuopyram is structurally
similar to wact-11 and has recently been developed as part of a
crop spray used to kill parasitic nematodes of plants22,23. We
tested ﬂuopyram and the other structurally related compounds,
along with established complex II inhibitors that are structurally
unrelated to the wact-11-family (Supplementary Fig. 6), for their
ability to kill C. elegans. None of these complex II inhibitors are
nematicidal up to the highest concentrations tested (120 mM),
except for ﬂuopyram and benodanil, which have LD100 values of
0.469 mM and 120 mM, respectively (Table 2; Supplementary
Fig 7). We found that the wact-11-resistant mutants also resist the
lethality induced by ﬂuopyram and benodanil (Supplementary
Fig. 7), suggesting that these molecules also target complex II
in vivo. We also tested the ability of the Q-site inhibitors to
inhibit C. elegans complex II in vitro. Only ﬂuopyram had a
potent IC50 (1.8 nM), which is almost 2-fold less inhibiting than
our two most potent wact-11-family analogues, wact-11 f and
wact-11m.
SDHB
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Figure 4 | Complex II residues that are mutated in the wact-11 family resistant mutants cluster near the ubiquinone-binding site (Q-site).
(a) Rendering of the crystal structure of Ascaris suum Complex II bound to the Q-site inhibitor ﬂutolanil (PDB: 3VRB). The side chains of the 14 orthologous
residues that are mutated in the wact-11-family resistant mutants are shown as opaque spheres. The atoms of the bound ﬂutolanil molecule are shown as
orange-coloured opaque spheres. (b) Close-up view of ﬂutolanil bound at the Q-site of Complex II from Ascaris suum. The 12 residues shown are no more
than 4Å away from ﬂutolanil, and make up the ﬂutolanil binding pocket. Intermolecular distances are indicated with bidirectional arrows. The dashed line
represents a hydrogen bond (H-bond) interaction. Only those H-bonds that occur between Complex II residues and ﬂutolanil are shown; H-bonds that
occur between residues of Complex II were omitted for clarity. Bound cofactors, and a bound fumarate molecule, were also omitted for clarity.
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The wact-11 family fails to inhibit mammalian complex II. The
evidence we have presented supports the idea that mitochondrial
complex II is the in vivo target of the wact-11-family in nema-
todes. Because the wact-11 family kills nematodes but not human
cells, we hypothesized that mammalian complex II is insensitive
to these compounds. We tested this hypothesis by assaying the
ability of wact-11, wact-12 and wact-11 f to inhibit murine
complex II in vitro. Mouse complex II was insensitive to the
highest concentrations tested (10 mM) for all three of these
compounds (Table 2; Supplementary Fig. 5).
To better understand the phylogenetic selectivity of the wact-
11 family, we inspected the conservation among the SDH
subunits in nematodes and vertebrates (Supplementary Fig. 8a).
First, we found that 12 of the 14 resistance-conferring residues are
conserved in all 10 nematode species examined. Of the two that
diverge, SDHC-1’s C78 diverges in only one of the 10 species and
SDHD-1’s A97 diverges in only two species. In each case, the
substitutions are conservative. These observations suggest that
nematodes may in general be sensitive to the wact-11-family of
compounds. Second, we analysed the conservation of the 14
residues among seven vertebrate sequences and found that ﬁve of
the 14 residues are divergent in all vertebrates examined with four
of these substitutions being nonconservative (Supplementary
Fig. 8b). Given that mutations of any single one of these residues
is sufﬁcient to confer resistance to the wact-11-family, it is
reasonable to infer that the vertebrate substitutions at these
positions will confer resistance to the wact-11 family of
nematicides.
Table 2 | Complex II IC50 and in vivo LD100 values for wact-11-family molecules and known complex II inhibitors.
Compound R1* R2* Species Strain SDHC
residue
change
In vitro
Complex II
IC50 (nM)
w
In vivo
LD100 (lM)z
wact-11 2-CF3 Ph (4’-Cl) C. elegans N2 None 7.4 7.5
RP2674 R74K 410,000 4120
RP2698 R74K 410,000 4120
M. musculus C57Bl/6 None 410,000 ND
wact-12 2-I OPh (4’-CH2CH3) C. elegans N2 None 5.7 7.5
RP2674 R74K 410,000 4120
RP2698 R74K 410,000 4120
M. musculus C57Bl/6 None 410,000 ND
wact-11f 2-CF3 Ph (2’-Cl, 4’-Cl) C. elegans N2 None 1.0 0.469
RP2674 R74K 410,000 4120
RP2698 R74K 410,000 4120
M. musculus C57Bl/6 None 410,000 ND
wact-11a 2-CF3 Ph C. elegans N2 None 26.1 60
wact-11i 2-CF3 CH2CH3 C. elegans N2 None 327.2 4120
wact-11g 4-CF3 Ph (4’-Cl) C. elegans N2 None 410,000 4120
wact-11p 2-I Ph (4’-Cl) C. elegans N2 None 5.8 7.5
wact-11e 2-I Ph (4’-F) C. elegans N2 None 15.3 60
wact-11d 2-Br Ph (4’-Cl) C. elegans N2 None 7.5 1.875
wact-11m 2-Br Ph (2’-Cl, 4’-Cl) C. elegans N2 None 1.0 0.469
wact-11j 2-Br CH2CH3 C. elegans N2 None 269.6 120
wact-11c 2-F Ph (4’-Cl) C. elegans N2 None 170.1 60
wact-11b - Ph (4’-Cl) C. elegans N2 None 632.9 4120
wact-11k - CH2CH3 C. elegans N2 None 410,000 4120
wact-12b 2-I OPh (4’-CH3) C. elegans N2 None 7.7 7.5
wact-12c 2-I SPh (4’-CH3) C. elegans N2 None 132.9 4120
wact-12d 2-I SPh (4’-Cl) C. elegans N2 None 128.5 4120
wact-12e 2-Br OPh (4’-Cl) C. elegans N2 None 7.8 30
Benodanil C. elegans N2 None 186.2 120
Boscalid C. elegans N2 None 549.5 4120
Carboxine C. elegans N2 None 410,000 4120
Diazoxide C. elegans N2 None 410,000 4120
Fenfuran C. elegans N2 None 5,279.0 4120
Fluopyram C. elegans N2 None 1.8 0.469
Flutolanil C. elegans N2 None 311.2 4120
Harz C. elegans N2 None 410,000 4120
Thiﬂuzamide C. elegans N2 None 3,819 4120
TTFA C. elegans N2 None 410,000 4120
Atpenin A5y C. elegans N2 None 1,678 4120
M. musculus C57Bl/6 None 593.3 ND
Malonate|| C. elegans N2 None 4.9 106 4120
RP2674 R74K 4.2 106 ND
RP2698 R74K 4.2 106 ND
Harz, harzianopyridone; ND, not determined; TTFA, thenoyltriﬂuoroacetone.
*The wact-11-family core structure, with the positions of the R1 and R2 groups indicated, is shown in Fig. 3
wThe inhibitory curves used to generate the complex II IC50 values can be found in Supplementary Fig. 5.
zThe in vivo LD100 value is deﬁned as the lowest concentration at which no viable animals are visible in four out of four replicate wells, 6 days after 20 ﬁrst larval-stage worms are deposited. The LD100
was determined from a 4-fold dilution series from 120 to 0.00183mM, and including 60 mM.
yFor mouse complex II experiments, atpenin A5 was used as a positive control.
||For the RP2698 and RP2674 complex II experiments, malonate was used as a positive control.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8485 ARTICLE
NATURE COMMUNICATIONS | 6:7485 | DOI: 10.1038/ncomms8485 | www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Discussion
Two factors may have discouraged the use of C. elegans as a
primary high-throughput screening tool to identify novel
anthelmintics. First, it is not a parasite and therefore lacks many
of the adaptations required for parasitism and the potential
anthelmintic targets associated with those processes16. Second,
the rapid evolution of species within phylum nematoda suggests
that C. elegans may have essential gene products that may
function differently or not exist in some parasitic species33.
Hence, many of the compounds that kill C. elegans may not be
effective against parasitic nematodes. However, our work has
revealed that molecules that do kill C. elegans are more than 15
times more likely to kill parasitic nematodes compared with
randomly selected molecules. Given that parasitic nematodes are
difﬁcult to screen in high throughput, these results make
pre-screening with C. elegans an attractive option to increase
the throughput of future anthelmintic discovery campaigns.
As expected, not all molecules that kill C. elegans are effective
against the parasitic models that we tested. In addition, by ﬁrst
screening in C. elegans, we have certainly missed molecules that
are effective at killing parasitic nematodes but are ineffective in
C. elegans. However, the speed and ease at which molecules can
be screened using C. elegans may outweigh the disadvantages it
carries as a primary screening system. In principle, C. elegans can
be used to evaluate hundreds of thousands of molecules at
multiple concentrations at a fraction of the cost and time that
would be required with most parasitic nematode models.
The extent to which our hits have broad-spectrum activity
against distantly-related nematodes is unknown. However,
C. elegans, C. oncophora and H. contortus are all clade V
nematodes and so molecules that are active against all three of
these species are more likely to have broad activity against
multiple species in this clade, which include many important
parasites of humans and animals34.
Using forward small molecule screens to identify anthelmintic
leads is a powerful approach because it makes no assumptions
about what kind of protein makes a good target. Furthermore, these
screens have the potential to yield phylum-speciﬁc compounds
with unexpected and conserved targets that may not have been
considered in target-based searches. Our discovery of the activity
and target of the wact-11 family provides a good proof-of-principle
for the utility of C. elegans as a pre-screening model system.
Multiple lines of evidence show that the wact-11 family targets
the conserved complex II of the electron transport chain in vivo.
First, a good correlation exists between complex II in vitro
inhibition and in vivo potency. Second, out of 33 mutants that
resist the wact-11-family, 32 have missense mutations in residues
that surround the ubiquinone-binding pocket of complex II. By
contrast none of the 36 strains that resist unrelated molecules
have mutations in complex II. Third, in vitro assays show that the
wact-11-family can inhibit complex II from wild-type worms but
not from worms that have a mutation in complex II that confers
resistance to these molecules in vivo. Together, these results
indicate that the wact-11 family kills C. elegans through its
inhibition of complex II.
Our screens have revealed that phylogenetically selective
bioactivity is highly dependent upon molecular structure. A
systematic analysis of close structural analogues revealed 17 pairs
of molecules whose phylogenetic bioactivity proﬁle becomes
restricted to nematodes with only small alterations in structure.
In addition to the 30 groups of anthelmintic lead structures we
describe above, the 275 C. elegans-lethals comprised 61 structural
groups, 33 of which do not contain a single molecule that kills
nematodes selectively. However, given the structure–bioactivity
analyses presented above, it may be possible to identify structural
analogues that speciﬁcally kill nematodes for at least some of
these structural groups, raising the total number of potential
anthelmintic lead structural classes beyond 30.
Of the 30 distinct groups of anthelmintic leads that we have
uncovered, we have attempted to screen for resistance against 16
representative molecules and have failed to generate resistance
against all but three. The reason behind this is unclear. Typically,
we use ethyl methanesulfonate as a mutagen in our genetic
screens, which is biased towards inducing G/C to A/T transi-
tions35 and therefore limits the type of non-synonymous
mutations that are induced. This is unlikely to explain the lack
of success, however, since we also carried out resistance screens
using the N-ethyl-N-nitrosourea mutagen35, which produces a
variety of nucleotide transitions and transversions, but was
equally unsuccessful in yielding resistant mutants (Supplementary
Table 1). Instead, we think it more likely that for most lethal
molecules, there is no single mutation in the respective target that
is capable of conferring resistance. This explanation might be
especially true for molecules that inhibit an essential target. It
may be that only rare essential targets (like complex II) can be
mutated to disrupt the efﬁcacy of an inhibitor without disrupting
the target’s activity below a viable state. Alternatively, it is possible
that many lethal molecules may have multiple essential targets. If
true, the generation and isolation of a single mutant animal that
has all of the targets mutated to confer resistance would be an
exceptionally rare event.
The inability to generate resistant mutants against these
molecules has two implications. The ﬁrst is trivial in that
approaches aside from genetics will have to be exploited to identify
the target(s) of these molecules. The more important implication is
that if the evolution of resistance in the lab can foretell evolution in
the ﬁeld, and there is good evidence for this3,5–8,13,14, then perhaps
the converse is true and that the set of anthelmintic leads for which
we are unable to generate resistance should be high priority
compounds for further development. Regardless, the evolution of
parasitic resistance does not immediately negate the usefulness of an
anthelmintic. For example, C. elegans mutants that resist the
effects of benzimidazoles, imidazothiazoles and cyclooctade-
psipeptides can be readily generated in the lab14,36, yet these
molecules have been effective in the ﬁeld for many years despite the
eventual emergence of resistance.
Materials and methods
Chemical sources. The sources for the chemicals and chemical libraries used in
our preliminary screens are indicated in Supplementary Data 1. The wact-11-
family and structural analogues were purchased from ChemBridge Corporation.
The established complex II inhibitors were purchased from Sigma-Aldrich, with
the exception of atpenin A5 and harzianopyridone, which were purchased from
Enzo Life Sciences, and thiﬂuzamide, which was purchased from AnGene.
C. elegans strains and culture methods. All the animals were cultured using
standard methods at 20 C (ref. 37), unless otherwise indicated. The N2 (wild-type)
strain of Caenorhabditis elegans was obtained from the C. elegans Genetics Center
(University of Minnesota).
C. elegans liquid-based chemical screening. The 96-well liquid-based chemical
screening assay was adapted from an established RNAi screening protocol38.
Brieﬂy, saturated HB101 Escherichia coli culture was concentrated 2-fold using
NGM (nematode growth media) containing 3mgml 1 NaCl, 2.5mgml 1
peptone, 5 mgml 1 cholesterol, 1mM CaCl2, 1mM MgSO4 and 25mM KH2PO4.
A total of 40ml of NGMþHB101 was dispensed into each well of a 96-well plate,
and chemicals were pinned into the wells using a pinning tool with a 300 nl slot
volume (V&P Scientiﬁc). Approximately 20 synchronized ﬁrst larval-stage (L1)
worms, in 10 ml of M9 buffer (see ref. 24 for the recipe), were then added to each
well. The synchronized L1s were obtained from an embryo preparation (see ref. 24
for the protocol) performed the previous day. The ﬁnal concentration of dimethyl
sulfoxide (DMSO) in the wells was 0.6% v/v. A dissection microscope was used to
visualize the wells either 5 or 6 days post worm deposition and any obvious
chemical-induced phenotypes were noted.
For our preliminary screens, 50,596 out of 67,012 compounds were assayed in
liquid at a 60mM concentration, and the other 16,416 molecules were screened on
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8485
8 NATURE COMMUNICATIONS | 6:7485 | DOI: 10.1038/ncomms8485 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
solid media at 25 mM (see ref. 24 for a description of our solid-based screening
method). From these screens, 672 compounds that induced at least a partially
penetrant phenotype were re-ordered and arrayed into a 10-plate ‘worm active’ or
‘wactive’ library. One hundred and eighty-two molecules chosen at random from
the 67,012 compounds were also included in the wactive library, along with many
DMSO control wells distributed across the plates.
Using the liquid-based assay, the re-ordered wactive library was re-screened in
worms at 7.5, 30 and 60 mM concentrations. Chemicals that induced an obvious
phenotype were classiﬁed as follows: ‘very strong’ molecules induced 100% lethality
at 7.5 mM, ‘strong’ molecules induced 100% lethality at 30 mM, ‘medium’ molecules
induced 100% lethality at 60 mM, ‘weak’ molecules induced incompletely penetrant
lethality at 60mM and ‘PEP’ molecules induced a non-lethal post-embryonic
phenotype such as dumpy (Dpy) or uncoordinated (Unc). The 275 C. elegans-
lethals that are referred to in the text are made up of the ‘very strong’, ‘strong’ and
‘medium’ molecules.
The 96-well liquid-based assay was also used for all follow-up dose-response
experiments in this work. These experiments were carried out in quadruplicate,
and the total number of worms in each well was counted 6 days after worm
deposition.
C. oncophora and H. contortus chemical screens. Fresh cattle and sheep faeces
containing eggs of an ivermectin-resistant strain of C. onchophora39 and the
MHco3(ISE) strain of H. contortus40,41, respectively, were kindly supplied by
Dr Doug Colwell and Dawn Gray (Lethbridge Research Station, Agriculture and
Agri-Food Canada). Experimental infections used to generate this material were
carried out using established methods39,41, and were approved by the Lethbridge
AAFC Animal Care committee and conducted under animal use license ACC1407.
Cattle faeces containing C. onchophora eggs were stored anaerobically at 4 C for a
maximum of 3 weeks, whereas sheep faeces containing H. contortus eggs were
stored at 20 C for no more than 48 h before harvesting eggs for use. Eggs were
isolated from faeces using a standard saturated salt ﬂotation method42 immediately
before each egg hatch assay. Approximately 100 eggs suspended in 100 ml of water
were added to each well of a 96-well plate, and the wactive library chemicals were
screened at two different concentrations (7.5 and 60 mM, 0.6% DMSO v/v).
Baseline egg hatch rates were determined in DMSO control wells B48 h after the
initial set-up of the assay by the addition of iodine tincture to stop development.
Plates having DMSO control wells with hatch rates470% were assayed on a semi-
quantitative gradient of ‘–’ to ‘þ þ þ ’, where ‘–’ wells had a hatch rate ofo10%,
and ‘þ þ þ ’ wells had a hatch rate close to wild type (usually 480%). A
dissection microscope was used for visualization purposes. Chemicals were
considered bioactive if they consistently had a ‘–’ in more than one trial, with ‘very
very strong’ assigned to compounds that were 90–100% lethal at 7.5 mM in all
replicates, ‘very strong’ if the same was true at 60 mM, ‘strong’ if replicates had a
hatch rate between 10 and 50%, ‘medium’ if replicates had a 50–80% hatch rate and
‘weak’ if only one replicate was between 50 and 80% hatch rate. A molecule was
considered ‘lethal’ if it exhibited ‘very very strong’ or ‘very strong’ bioactivity.
Zebraﬁsh culture and chemical screening. Wild-type (AB) zebraﬁsh embryos
were collected in E3 solution (5mM NaCl, 0.17mM KCl, 0.33mM CaCl2, 0.33mM
MgSO4) immediately after fertilization and arrayed at three embryos per well in
96-well plates, 200 ml per well. Wild-type (AB) zebraﬁsh were originally obtained
from Zebraﬁsh International Resource Center (University of Oregon). Chemicals
were added to each well at 6 h post fertilization at a ﬁnal concentration of 10 mM
(0.5% v/v DMSO), with each plate containing nine wells of DMSO controls.
Embryos were examined for mortality and observable developmental phenotypes at
24 and 48 h post fertilization using an Olympus SZX10 Brightﬁeld microscope.
Phenotypes examined were death, developmental delay, reduced pigmentation,
cranial oedema or cardiac defects (slow/absent heart rate, abnormal heart size).
Each compound was screened in duplicate, with only phenotypes appearing in both
replicates associated with a given compound. Any compound producing multiple,
distinct phenotypes across replicates (for example, cardiac defects in one replicate,
mortality in another) was labelled ‘toxic’. A molecule was considered ‘lethal’ to
zebraﬁsh if it induced ‘death’ or ‘toxicity’.
HEK293 cell culture and chemical screening. HEK293T cells (Attisano Lab,
University of Toronto) were maintained in Dulbecco’s Modiﬁed Eagle’s Medium
(Gibco) supplemented with 10% FBS (DMEM-10% FBS). Cells at a concentration
of 50 cells ml 1 were seeded into 96-well plates at a ﬁnal volume of 100 ml (B5,000
cells per well). Chemicals from the wactive library were added to the wells for a
ﬁnal concentration of 60 mM (0.6% DMSO v/v). The wactive library plates were
screened at least in triplicate. Cell proliferation was determined using a bromo-
deoxyuridine (BrdU) assay kit (Exalpha Biologicals Inc.). The BrdU was added 2
days after chemical addition. Fixation and denaturation was performed B16–18 h
later. Anti-BrdU antibody was added, and incorporated BrdU was detected using a
horseradish peroxidase-conjugated goat anti-mouse antibody. The BrdU incor-
poration signal was measured at 450/550 nm for the amount of conversion of tetra-
methylbenzidine that is proportional to the amount of BrdU incorporated. For
each replicate of each plate, the average signal for the DMSO control wells was
calculated. For each well in the plate (including the DMSO control wells), the signal
was normalized by dividing by the average DMSO signal. The mean and standard
deviation for the population of 960 normalized sample signals of the 10-plate
wactive library were calculated and found to be 0.6 and 0.44, respectively. A
molecule was considered ‘lethal’ if its normalized signal had a magnitude o0.16
(that is, a value less than the s.d. subtracted from the mean).
Cheminformatics. Chemical structures as supplied by the manufacturers were
analysed using the ChemAxon calculator (http://www.chemaxon.com). Speciﬁcally,
number of hydrogen bond donors, number of hydrogen bond acceptors, mass,
atom count, rotatable bond count, logP (a measure of hydrophobicity), Van der
Waals surface area, polar surface area, Van der Waals volume and refractivity were
computed using default parameters. In the case of salts, all properties were cal-
culated on the largest molecule. Pairwise similarity scores were calculated as the
Tanimoto coefﬁcient of shared FP2 ﬁngerprints using OpenBabel (http://open-
babel.org). An FP2 ﬁngerprint is a linear fragment of a molecule, containing one to
seven atoms. Each pair of compounds to be analysed for similarity were evaluated
for presence or absence of any of thousands of possible FP2 ﬁngerprints, and the
Tanimoto coefﬁcient represents the number of ﬁngerprints in common between
the two compounds divided by the total number of ﬁngerprints present in both
compounds. Network visualization for Fig. 2b was performed using Cytoscape43.
Forward genetic screens for resistant mutants. Our forward genetic screens
were carried out as previously described9,24. In brief, wild-type parental (P0)
worms were mutagenized in 50mM ethyl methanesulfonate for 4 h, or in 0.5mM
N-ethyl-N-nitrosourea for 4 h, as previously described. Tens of thousands of
synchronized L1s from either the F1 (progeny) or F2 (grand-progeny) generations
were dispensed onto 10 cm MYOB agar plates (see ref. 24 for how to prepare
MYOB/agar media) containing anB100% penetrant lethal dose of the nematicide.
Candidate-resistant mutants are those worms that can grow in the presence of the
chemical. Candidates were picked onto solid MYOB plates without any added
chemical, and 12 of their progeny were individually re-tested on a 100%-penetrant
lethal dose of the nematicide. Those candidates that re-tested were subsequently
homozygosed as previously described9,24.
Whole-genome sequencing of wact-11-family-resistant mutants. A total 100ml
of packed worms were harvested in a 15ml conical tube and washed three times
with M9 buffer. The worms were then incubated in 6ml of M9 buffer for 1 h on a
nutating shaker at 20 C. The worms were then washed once with 1 phosphate-
buffered saline (PBS) buffer. The tube was centrifuged and the PBS buffer was
aspirated without disturbing the worm pellet. The worms were ﬂash frozen in
liquid nitrogen and ground with a pestle until the pellet defrosted. The DNeasy
Blood and Tissue Kit (Qiagen) was used to lyse the worm cells and purify the
genomic DNA. The Nextera DNA Sample Preparation Kit (Illumina) was used to
generate the genomic DNA libraries for sequencing. Individual libraries were
quantiﬁed with quantitative PCR with reverse transcription using KAPA standards.
Multiplexed libraries were sequenced on an Illumina HiSeq2500, paired end reads,
125 bp 125 bp, using version 4 reagents and ﬂow cells.
Sequence variants were identiﬁed using a BWA-GATK pipeline. Brieﬂy, the
125-bp sequencing reads were examined for sequence quality using FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and bases lower than a
quality threshold of 30 were trimmed off using Trimmomatic44. Reads were aligned
to the C. elegans N2 reference genome (release W220) using BWA-mem45.
Alignments were sorted by coordinate order and duplicates removed using Picard
(http://picard.sourceforge.net). Before variant calling, reads were processed in
Genome Analysis Tool Kit (GATK) v2.5 (ref. 46) for indel realignment and base
quality score recalibration, using known C. elegans variants from dbSNP build 138
(http://www.ncbi.nlm.nih.gov/SNP/). GATK HaplotypeCaller was used to call
variants, and results were ﬁltered for a phred-scaled Q score 430. Finally, called
variants were annotated using Annovar47 to obtain a list of exonic variants for each
sample.
Ascaris suum complex II structure rendering. PyMOL48 was used to generate the
images in Fig. 4a,b, using the crystal structure 3VRB (downloaded from the Protein
Data Bank). H-bonds were identiﬁed by performing the ‘ﬁnd4polar contacts’
action in PyMOL48, using the default settings.
Mitochondria isolation from worms. HB101 E. coli cells (C. elegans Genetics
Center, University of Minnesota) from a 1 l saturated culture were pelleted by
centrifugation at 2,500g for 10min, and then resuspended in 50ml complete
S-medium (see ref. 37 for recipe). In all, 450,000 synchronized ﬁrst larval-stage
worms, in M9 buffer, were added to the S-media/HB101 suspension and were
grown to adulthood over 3.5 days at 20 C with shaking at 200 r.p.m. Worms were
collected in 6 15ml conical tubes and washed eight times with M9 buffer. The
worms from the six tubes were combined into one 15ml conical tube, and
resuspended in 15ml M9 buffer. One millilitre aliquots of the worm suspension
were distributed to each of the 15 1.5ml Sarstedt microcentrifuge tubes. The
worms were pelleted by centrifugation at 800g, and the M9 buffer was aspirated
without disrupting the pellet. A total 600 ml of cold isolation buffer A (250mM
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sucrose, 10mM Tris (pH 7.5), 1mM EDTA, 1mM PMSF) was added to each tube.
A total 300ml of cold glass beads was added to each tube. The tubes were cooled on
ice for 10min, and the worms were disrupted by bead beating 6 30 s, with 1min
cooling intervals. The tubes were spun down at 1,000g for 10min at 4 C and the
supernatants were transferred to a single 15ml conical tube on ice. The
homogenate was centrifuged at 1,000g for 10min at 4 C. The supernatant was
transferred to a new cold tube, and centrifuged at 16,000g for 10min at 4 C. The
pellet was washed twice by re-suspending gently in 5ml of cold isolation buffer B
(250mM sucrose, 10mM Tris (pH 7.5), 1mM EDTA). After the ﬁnal wash, 310 ml
aliquots of the mitochondrial suspension were distributed across 16
microcentrifuge tubes and the tubes were centrifuged at 16,000g for 10min at 4 C.
The supernatant was aspirated and the pellets were snap frozen in liquid nitrogen
and stored at  80 C until needed.
Mitochondria isolation from mouse liver. The livers from three 8–10-week-old
C57Bl/6 female mice (Charles River) were removed, collected in 1.5ml micro-
centrifuge tubes, ﬂash frozen in liquid nitrogen and stored at  80 C until needed.
Just before mitochondria isolation, the livers were weighed, placed into a 10-cm
petri dish and 10ml isolation buffer A was added per gram of liver tissue. The
tissue was ﬁnely minced with a razor blade, transferred to a glass Dounce homo-
genizer and homogenized by 10 strokes on ice. The homogenate was centrifuged at
1,000g for 10min at 4 C. The supernatant was collected and centrifuged at 1,000g
for 10min at 4 C. The supernatant was again collected and centrifuged at 16,000g
for 10min at 4 C. The pellet was resuspended in 20ml of isolation buffer B and
centrifuged at 16,000g for 10min at 4 C. The pellet was resuspended in 20ml of
isolation buffer B, and 1ml aliquots of the resuspension were distributed into
20 1.5ml microcentrifuge tubes. The aliquoted resuspensions were centrifuged at
16,000g for 10min at 4 C. The supernatant was aspirated, the pellet was ﬂash
frozen in liquid nitrogen and stored frozen at  80 C until needed. The mice used
for experimentation were housed and used in accordance with ‘the use and care of
experimental animals’ guidelines. The animal protocols were reviewed and
approved by the Animal Care Committee of the University of Toronto.
Cell-free Complex II functional assay. Mitochondrial pellets were thawed on ice
and resuspended in 300ml of cold isolation buffer B. Using the BCA assay49, the
protein concentration of the mitochondria suspension was determined and was
subsequently diluted to a concentration of 0.2mgml 1 with cold isolation buffer
B. Complex II enzymatic assays were carried out in 96-well ﬂat bottom plates. A
total 150 ml of complex II assay buffer (1X PBS, 0.35% BSA, 20mM succinate,
240mM KCN, 60mM DCIP, 70mM decylubiquinone, 25mM antimycin A, 2 mM
rotenone) containing dissolved compounds at the desired concentration, or DMSO
(2.4% v/v) alone for control purposes, was added to each well. All of the
compounds tested were dissolved in DMSO, except malonate, which was dissolved
in water, so DMSO was omitted from the malonate control wells. Five microlitres
of the 0.2mgml 1 mitochondria suspension was added to each well and mixed by
pipetting up and down ﬁve times. Absorbance for each well was measured at
600 nm using a SpectraMax Plus 384-well Microplate Reader, combined with
SoftmaxPro software at 30-s intervals over a 35-min time period. Absorbance
versus time was plotted for each well and enzyme activity was calculated as the
slope of the line deﬁned by the points ranging from 4 to 10min. Per cent activity
was calculated by dividing the enzyme activity of the chemical-treated wells by that
of the DMSO control wells. The per cent activity plotted in Supplementary Fig. 5 is
the average of four technical replicates.
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